spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:   ALS  

 HSMN NewsFeed - 28 Jul 2026
BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 2 Jul 2026
Spinogenix Appoints Professor Joseph T. Coyle, MD, Current Chair of Psychiatry and Neuroscience at Harvard Medical School, to Scientific Advisory Board
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 26 Feb 2026
Brainstorm Cell Therapeutics Secures Second $1 Million Strategic Placement; Total $2 Million Raised In February
Regenerative Medicine Neurology Venture Capital
 HSMN NewsFeed - 20 Feb 2026
Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market
Regenerative Medicine Neurology Venture Capital
 HSMN NewsFeed - 27 Aug 2025
Leal Therapeutics Announces $30 Million Series A to Progress First-In-Class Neuro-Metabolic Therapies for Neurodegenerative and Neuropsychiatric Disorders with High-Unmet Need
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 10 Jul 2025
Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis ("ALS" or "Lou Gehrig's Disease")
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 27 May 2025
BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn(R) Phase 3b ALS Clinical Trials
Regenerative Medicine Neurology
 HSMN NewsFeed - 19 May 2025
BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn(R) for ALS
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 5 May 2025
Spinogenix Announces FDA-Authorized Expanded Access Program for SPG302, the First Synaptic Regenerative Therapy to Treat ALS
Biopharmaceuticals Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 10 Apr 2025
BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 26 Jun 2024
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn(R) Clinical Trial
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 20 Jun 2024
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 17 Jun 2024
Raya Therapeutic Announces Supportive Clinical Results of Fasudil (RT1968) in ALS Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 8 Apr 2024
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS(R) (edaravone)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 23 Feb 2024
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 24 Oct 2023
BrainStorm Cell Therapeutics Announces Strategic Realignment Prioritizing NurOwn(R) for the Treatment of ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 18 Oct 2023
BrainStorm Cell Therapeutics to Meet with US FDA to Discuss Development Plan for NurOwn as a Treatment of ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 12 Jul 2023
BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 27 Mar 2023
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn(R) for the Treatment of ALS
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 9 Mar 2023
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 27 Dec 2022
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 10 Nov 2022
BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS
Biopharmaceuticals Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 15 Sep 2022
BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn(R) Phase 2 Progressive MS Trial in Multiple Sclerosis Journal
Regenerative Medicine Neurology
 HSMN NewsFeed - 15 Jun 2022
RADICAVA ORS(R) (edaravone) Now Available in the U.S. for the Treatment of ALS
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 18 May 2022
ProJenX Names Life Sciences Industry Veteran Stan E. Abel as CEO
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 21 Mar 2022
NeuroSense Therapeutics Receives FDA Clearance of IND for PrimeC for the Treatment of ALS
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 8 Feb 2022
FDA Approves JUVÉDERM(R) VOLBELLA(R) XC for Undereye Hollows
Devices Dermatology FDA
 HSMN NewsFeed - 5 Jan 2022
Neuvivo Expands Management Team Adding Gregg Fergus, Former President of Ion Torrent, as Head of Strategy and Business Development and to the Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 27 Dec 2021
FDA Authorizes Further NurOwn(R) Dosing Under Expanded Access Program
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 8 Nov 2021
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 30 Jun 2021
Mitsubishi Tanabe Pharma America Announces EXSERVAN(TM) (riluzole) is Now Available in the U.S. for the Treatment of ALS
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 5 Apr 2021
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Biopharmaceuticals Neurology
 HSMN NewsFeed - 4 Jan 2021
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
Biopharmaceuticals
 HSMN NewsFeed - 14 Dec 2020
BrainStorm Announces NurOwn(R) Expanded Access Program
Regenerative Medicine Neurology Product Launch
 HSMN NewsFeed - 23 Nov 2020
BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
Regenerative Medicine Neurology
 HSMN NewsFeed - 17 Nov 2020
BrainStorm Announces Topline Results from NurOwn(R) Phase 3 ALS Study
Regenerative Medicine Neurology
 HSMN NewsFeed - 15 Oct 2020
Lilly Announces Agreement to Acquire Disarm Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Sep 2020
BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region
Biopharmaceuticals Personnel Venture Capital
 HSMN NewsFeed - 2 Sep 2020
Letter from Seneca Biopharma's Executive Chairman
Biopharmaceuticals
 HSMN NewsFeed - 24 Aug 2020
Yumanity Therapeutics and Proteostasis Therapeutics Announce Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Jun 2020
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
Regenerative Medicine Neurology
 HSMN NewsFeed - 22 Jun 2020
FDA Accepts Supplemental Biologics License Application (sBLA) for BOTOX(R) (onabotulinumtoxinA) for the Treatment of Pediatric Patients with Neurogenic Detrusor Overactivity
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 27 May 2020
BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 8 May 2020
FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 30 Apr 2020
Alpha Cognition, Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 18 Mar 2020
Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Feb 2020
Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 18 Nov 2019
Allergan(R) Announces First Annual National BOTOX(R) Cosmetic (onabotulinumtoxinA) Day
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 24 Oct 2019
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Lower Limb Spasticity, Excluding Spasticity Caused by Cerebral Palsy
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Sep 2019
Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey & AMG Center For Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 31 Jul 2019
Biohaven Enrolls First Patient In Phase 3 Clinical Trial Of Verdiperstat, Oral Myeloperoxidase Inhibitor, For The Treatment Of Multiple System Atrophy
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Jun 2019
FDA Approves BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Mar 2019
FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX(R) (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Dec 2018
Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 Nov 2018
Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology Drug Delivery FDA
 HSMN NewsFeed - 23 Oct 2018
CavoGene LifeSciences Licenses Novel Gene Therapy for CNS Disorders
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 3 Oct 2018
Rewind Therapeutics Appoints Leading Neuroscience Drug Developer Ian J. Reynolds as Chief Executive Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 12 Sep 2018
Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 12 Sep 2018
Biohaven Appoints Bob Repella to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 21 Aug 2018
ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies in Clinical Development
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 Jul 2018
Biohaven Receives FDA May Proceed Letter And Initiates Phase 2/3 Clinical Trial Of Trigriluzole (BHV-4157) In Alzheimer's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 28 Jun 2018
BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello
Regenerative Medicine Personnel
 HSMN NewsFeed - 28 Jun 2018
Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting
Biopharmaceuticals
 HSMN NewsFeed - 26 Apr 2018
Neuraltus Pharmaceuticals Reports Results from Phase 2 NP001 Study in Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 Mar 2018
BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 8 Mar 2018
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
Regenerative Medicine Neurology
 HSMN NewsFeed - 5 Feb 2018
BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 21 Dec 2017
Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Nov 2017
Mitsubishi Tanabe Pharma America Announces Addition of RADICAVA(R) (edaravone) to U.S. Department of Veterans Affairs National Formulary
Biopharmaceuticals Neurology Reimbursement
 HSMN NewsFeed - 16 Nov 2017
Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Nov 2017
BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 16 Oct 2017
BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 2 Oct 2017
Biohaven Reports Negative Topline Data from Spinocerebellar Ataxia (SCA) Phase 2/3 Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Aug 2017
PhRMA Announces Dr. Richard Moscicki as New Chief Medical Officer and Executive Vice President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Aug 2017
First FDA-Approved Treatment For ALS In 22 Years Now Available In U.S.
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 7 Aug 2017
BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government Affairs
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 4 Aug 2017
Biohaven Appoints Julia P. Gregory to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 31 Jul 2017
Biohaven Initiates Second Pivotal Phase 3 Clinical Trial of Oral CGRP Antagonist for the Acute Treatment of Migraine
Biopharmaceuticals Neurology
 HSMN NewsFeed - 25 Jul 2017
BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 21 Jul 2017
Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 18 Jul 2017
BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 6 Jul 2017
Biohaven's BHV-5000 Receives Orphan Drug Designation from the FDA in Rett Syndrome
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 22 Jun 2017
Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 9 Jun 2017
Kleo Pharmaceuticals Inc. Appoints Douglas J. Manion M.D. as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Mar 2017
BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 27 Feb 2017
BrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial Success
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 21 Feb 2017
BrainStorm Seeking Approval To Distribute NurOwn(R) in Canada
Regenerative Medicine Neurology Regulatory Distribution
 HSMN NewsFeed - 22 Nov 2016
Groundbreaking Team At Aquinnah Pharmaceuticals Adds Two New Members To Help Overcome The Challenge Of ALS And Alzheimer's Disease
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 17 Oct 2016
French Study Of NeuRx(R) Diaphragm Pacing System (DPS) In Off-Label ALS Patients Confirms: NeuRx DPS(R) Should Be Used With NIV In Later Stage Of Disease
Devices Neurology
 HSMN NewsFeed - 22 Sep 2016
Kleo Pharmaceuticals Inc. Appoints David A. Spiegel as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Sep 2016
Kleo Pharmaceuticals Inc. Appoints Roy Prieb as Chief Operating Officer and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jun 2016
NUEDEXTA(R) Effective for Pseudobulbar Affect (PBA) in Patients with Alzheimer's Disease and other Dementias, Stroke and Traumatic Brain Injury
Biopharmaceuticals Neurology
 HSMN NewsFeed - 9 Feb 2016
Alder BioPharmaceuticals Strengthens and Expands Leadership Team Supporting Advancement of ALD403 Toward Future Commercialization
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Jan 2016
U.S. FDA Approves BOTOX(R) (onabotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Jan 2016
Amylyx Announces Election of Nobel Laureate Walter Gilbert, PhD, to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 7 Dec 2015
BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen-Aricha as Vice President of Research & Development
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 9 Nov 2015
Avalon Ventures Expands Collaboration with GSK and Launches Seventh New Company at COI Pharmaceuticals
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 3 Aug 2015
BrainStorm Strengthens Executive Team: Announces the Appointment of Yoram Bibring as Chief Financial Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 15 May 2015
Zambon Launches Xadago(R) (safinamide) for Patients with Mid- to Late-Stage Parkinson’s Disease in Germany
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 14 May 2015
Denali Therapeutics Launches with Initial Investment to Discover and Develop Treatments for Neurodegenerative Diseases
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 1 Apr 2014
Mahendra Rao, MD, PhD Joins Q Therapeutics as Chief Strategy Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 25 Mar 2014
BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical Trial
Regenerative Medicine Neurology
 HSMN NewsFeed - 14 Jan 2014
Neuralstem Appoints Catherine Angell Sohn To Board Of Directors
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 5 Sep 2013
Neuralstem To Raise $4 Million In Registered Direct Offering
Regenerative Medicine Neurology Venture Capital
 HSMN NewsFeed - 14 Jan 2013
Neuralstem Receives FDA Approval To Commence Spinal Cord Injury Trial
Biopharmaceuticals Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 3 Jan 2013
Biogen Idec Reports Top-Line Results from Phase 3 Trial Investigating Dexpramipexole in People with Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 Jun 2012
Neuralstem Updates ALS Stem Cell Trial Progress; Emory University Institutional Review Board Approves Amendment
Biopharmaceuticals Regenerative Medicine Neurology
 HSMN NewsFeed - 14 May 2012
Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Oct 2011
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
Regenerative Medicine Neurology
 HSMN NewsFeed - 29 Sep 2011
Biogen Idec Promotes Tony Kingsley to Run Global Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jun 2011
Neuralstem Updates ALS Clinical Trial Progress
Regenerative Medicine Neurology
 HSMN NewsFeed - 10 Feb 2011
Neuralstem Updates ALS Clinical Trial Progress
Regenerative Medicine Neurology
 HSMN NewsFeed - 9 Feb 2011
Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
Biopharmaceuticals Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 24 Jan 2011
BrainStorm Appoints Dr. Adrian Harel as Chief Operating Officer and Acting Chief Executive Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 30 Oct 2010
AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Aug 2010
Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
Regenerative Medicine
 HSMN NewsFeed - 17 May 2010
Teva Provides Update on Talampanel for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 11 May 2010
BrainStorm Announces Significant Milestones Achieved and 2009 Review
Regenerative Medicine Neurology
 HSMN NewsFeed - 10 Mar 2010
Cytokinetics Announces Orphan Drug Designation Granted to CK-2017357 for the Treatment of Amyotrophic Lateral Sclerosis
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 21 Jan 2010
Neuralstem Announces First Patient Treated in ALS Stem Cell Trial
Regenerative Medicine Neurology
 HSMN NewsFeed - 13 Jan 2010
FDA Gives TCA Cellular Therapy Green Light to Proceed with First ALS Adult Stem Cell Trial Using Patient's Own Stem Cells
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 21 Dec 2009
California Stem Cell, Inc Closes Series B Financing Round
Regenerative Medicine Venture Capital
 HSMN NewsFeed - 8 Dec 2009
Stem Cell Based Treatment for Spinal Muscular Atrophy Receives Orphan Drug Designation
Regenerative Medicine FDA
 HSMN NewsFeed - 21 Sep 2009
Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 24 Aug 2009
BrainStorm Cell Therapeutics Secures Funding to Reach Clinical Trials for ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 5 Aug 2009
Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Apr 2009
ZOLL Receives Clearance to Market R Series Defibrillators in China
Devices Regulatory
 HSMN NewsFeed - 26 Mar 2009
Neuraltus Pharmaceuticals Raises $17 Million Series A Funding
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 16 Mar 2009
CytRx's Arimoclomol Demonstrates Statistically Significant Neurorestorative Results in a Preclinical Embolic Stroke Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Feb 2009
Neuralstem's ALS Trial on Clinical Hold
Regenerative Medicine Neurology
 HSMN NewsFeed - 22 Jan 2009
Zoll Receives Clearance to Market New R Series BLS and R Series Plus Defibrillators
Devices FDA
 HSMN NewsFeed - 2 Dec 2008
Targeted Genetics Realigns Product Development Priorities and Implements Cost Reduction Measures
Biopharmaceuticals
 HSMN NewsFeed - 14 Oct 2008
Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
Devices Drug Delivery Regenerative Medicine Neurology
 HSMN NewsFeed - 22 Sep 2008
CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Sep 2008
World Renowned ALS Expert From Harvard Medical School and Mass. General Hospital, Dr. Robert H. Brown Jr., Joins BrainStorm Cell Therapeutics Scientific Advisory Board
Regenerative Medicine Personnel
 HSMN NewsFeed - 21 Jul 2008
Insmed Provides Update on IPLEX(TM) Programs
Biopharmaceuticals
 HSMN NewsFeed - 9 Jun 2008
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 May 2008
Neuralstem Responds to New StemCells, Inc. Lawsuit
Regenerative Medicine Litigation
 HSMN NewsFeed - 7 May 2008
Neuralstem Sues StemCells, Inc. Over New Patent
Regenerative Medicine Neurology Litigation
 HSMN NewsFeed - 6 May 2008
Neuralstem Goes to Court for Summary Judgment Against StemCells, Inc.
Regenerative Medicine Neurology Litigation
 HSMN NewsFeed - 23 Apr 2008
Ceregene Announces Two Key Additions to Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Apr 2008
Cambria Pharmaceuticals Announces $5.4 Million Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 15 Apr 2008
Neuralstem Responds to Incorrect StemCells, Inc. Release on Patents
Regenerative Medicine Litigation
 HSMN NewsFeed - 13 Mar 2008
Teva Provides Update on Glatiramer Acetate 40mg for Amyotrophic Lateral Sclerosis (ALS)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 20 Feb 2008
Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
Regenerative Medicine Licensing
 HSMN NewsFeed - 15 Feb 2008
Q Therapeutics Announces Series B Investment
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 22 Jan 2008
Knopp Neurosciences Completes First Series B Financing of $10 Million
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 17 Dec 2007
CytRx Announces Management Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2007
Ceregene Promotes Dr. Raymond Bartus to Executive Vice President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Nov 2007
Neuralstem Obtains UCSD Stem Cell Delivery System for Use in Spinal Cord Trials
Regenerative Medicine Neurology Licensing
 HSMN NewsFeed - 12 Nov 2007
BrainStorm Cell Therapeutics Secures Significant Equity Financing and Raises Research Budget
Regenerative Medicine Neurology
 HSMN NewsFeed - 1 Nov 2007
Dawn McGuire, M.D. Joins Acologix, Inc. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Oct 2007
Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
Biopharmaceuticals FDA Neurology
 HSMN NewsFeed - 12 Oct 2007
Rami Efrati, Former VP Business Development and Marketing for NICE SYSTEMS' Government Division, Joins BrainStorm As CEO
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 8 Oct 2007
BrainStorm on the Verge of a Breakthrough Towards Developing a Cure for Lou Gehrig's Disease
Regenerative Medicine Neurology
 HSMN NewsFeed - 3 Oct 2007
Cheryl Fossum Graham Joins Knopp Neurosciences as Head of Regulatory and Development Strategy
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 24 Sep 2007
CytRx Provides Arimoclomol and Iroxanadine Clinical Trial Updates
Biopharmaceuticals Neurology Wound Care
 HSMN NewsFeed - 19 Sep 2007
Patent Office Rules in Neuralstem's Favor in Dispute with StemCells, Inc.
Regenerative Medicine Neurology Litigation
 HSMN NewsFeed - 12 Sep 2007
CytRx Names Mitchell K. Fogelman Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Sep 2007
CytRx Subsidiary RXi Pharmaceuticals Names Life Science Veteran Stephen J. DiPalma Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Aug 2007
FDA Grants Tikvah Therapeutics, Inc. Orphan Drug Status for Sodium Phenylbutyrate for the Treatment of Spinal Muscular Atrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Jun 2007
CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 Jun 2007
CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Dmitry Samarsky, Ph.D., as Vice President of Technology Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jun 2007
Amgen to Acquire Alantos Pharmaceuticals, a Private Biotechnology Company in Cambridge, Massachusetts
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 May 2007
Neuralstem's Cells Restore Motor Function in Spinal Ischemia-Paralyzed Rats
Regenerative Medicine
 HSMN NewsFeed - 22 May 2007
CytRx Names Shi Chung Ng, Ph.D., Senior Vice President of Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 May 2007
CytRx Provides Operational Update
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 May 2007
Dr. John P. Donoghue Presents on Cyberkinetics' BrainGate Neural Interface System in Plenary Session at the AAN Annual Meeting in Boston
Devices Neurology
 HSMN NewsFeed - 30 Apr 2007
Insmed Releases Positive Results from IPLEX Phase II HIV-Associated Adipose Redistribution Syndrome Clinical Study
Biopharmaceuticals HIV/AIDS
 HSMN NewsFeed - 24 Apr 2007
William C. Oldaker and Scott V. Ogilvie Join Neuralstem Board of Directors
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 10 Apr 2007
John Conron Joins Neuralstem as Chief Financial Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 22 Mar 2007
Avicena Announces Patient Enrollment in National Institutes of Health (NIH) Phase III Parkinson's Disease Trial
Biopharmaceuticals Neurology
 HSMN NewsFeed - 16 Mar 2007
Neuralstem Inc. Raises $5 Million in a Private Placement
Regenerative Medicine Neurology
 HSMN NewsFeed - 8 Mar 2007
CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Vice President of Pharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Mar 2007
Litigation Settlement Reached Between Tercica, Genentech and Insmed
Biopharmaceuticals Litigation
 HSMN NewsFeed - 11 Jan 2007
Neuralstem Licenses Out Compounds for Diabetes Treatment
Regenerative Medicine Licensing
 HSMN NewsFeed - 10 Jan 2007
Italian Ministry of Health Requests IPLEX(TM) for Treatment of ALS (Lou Gehrig's Disease)
Biopharmaceuticals Neurology Licensing Distribution
 HSMN NewsFeed - 9 Jan 2007
Stem Cell Innovations Announces Issuance of Fundamental Human Stem Cell Patent
Regenerative Medicine
 HSMN NewsFeed - 31 Oct 2006
CytRx's Arimoclomol Granted Orphan Drug Designation in European Union for Treatment of ALS
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 15 Oct 2006
Cyberkinetics' BrainGate System Enables Thought-Driven Communication Device and Wheelchair Control for First Stroke Participant in Pilot Clinical Trial
Devices Neurology
 HSMN NewsFeed - 14 Oct 2006
Cyberkinetics' BrainGate System Enables Thought-Driven Computer Control for First ALS Patient in Pilot Clinical Trial
Devices Neurology
 HSMN NewsFeed - 9 May 2006
Avicena Announces Phase III ALS Trial Results
Biopharmaceuticals Neurology
Return to NewsFeed  

 Additional items found! 49

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 49 additional stories matching:
ALS
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!